Both bariatric metabolic surgery (BMS) and treatment with GLP-1 receptor agonists (GLP-1 RAs) are offered to patients with obesity and diabetes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.